Additionally, anifrolumab, a human monoclonal antibody that binds to the type I interferon receptor (IFNAR1), met the primary endpoint in one Phase III trial (44, 45) and was recently approved in the US for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy (46). Here, IFNAR1 is linked to systemic lupus erythematosus.